ESMO 2014

Oncology Meeting Resources

26 Sep - 30 Sep 2014, Madrid, Spain

ESMO 2014 Congress

The theme for ESMO 2014 was ‘Precision Medicine in Cancer Care.’ Whether you are a medical or surgical oncologist or a radiation oncologist, immunologist or pathologist, practising precision medicine means we are all working towards a common goal – improved patient outcomes. For your convenience and due to the large quantity of information coming from the ESMO 2014 congress, we have split the presentations up by main congress topic to allow you to find the information you need more easily.

Here, you will find the abstracts, posters, PDF presentation and webcasts from ESMO 2014 to the extent the presenters have consented to release their contribution or a slightly modified version thereof. Please, note that the publication of these presentations is a courtesy of the originating authors and is for personal educational purposes only.

Drug Index of ESMO 2014 Abstracts

Special Sessions and Tracks

Useful links





Format available

http://oncologypro.esmo.org/Meeting-Resourc...4/The-best-approach-to-oligometastatic-NSCLC

Date: 27 Sep 2014
Presenter: Jaroslaw Kuzdzal
Resources: Presentation, Webcast
Topics: Anti-Cancer Agents & Biologic Therapy, Non-Small-Cell Lung Cancer, Locally Advanced, Surgery and/or Radiotherapy of Cancer

http://oncologypro.esmo.org/Meeting-Resourc...results-in-different-age-groups-70-yrs-70-yr

AimThis single arm multicenter Phase II study showed that Pem-Cis induction chemotherapy (CT) followed by full-dose Pem-Cis + concurrent radiotherapy (RT) was well tolerated and effective in pts with LA NS-NSCLC.

Date: 27 Sep 2014
Presenter: Pilar Garrido Lopez
Resources: Abstract
Topics: Anti-Cancer Agents & Biologic Therapy, Non-Small-Cell Lung Cancer, Locally Advanced, Surgery and/or Radiotherapy of Cancer

http://oncologypro.esmo.org/Meeting-Resourc...squamous-non-small-cell-lung-cancer-NS-NSCLC

AimThis study was designed to evaluate the response rate of Pem-Cis as preoperative CT in patients with stage IIIAN2 NS NSCLC. The neoadjuvant setting provided the opportunity to obtain tumor tissue...

Date: 27 Sep 2014
Presenter: Ugo Pastorino
Resources: Abstract
Topics: Anti-Cancer Agents & Biologic Therapy, Non-Small-Cell Lung Cancer, Locally Advanced

http://oncologypro.esmo.org/Meeting-Resourc...ts-with-Stage-III-non-small-cell-lung-cancer

AimStage III non-small cell lung cancer (NSCLC) is one of the most controversial areas in managing lung cancer and gives a chance to clinicians to practice the art of medicine.

Date: 27 Sep 2014
Presenter: Melike Ozcelik
Resources: Abstract
Topics: Anti-Cancer Agents & Biologic Therapy, Non-Small-Cell Lung Cancer, Locally Advanced, Surgery and/or Radiotherapy of Cancer

http://oncologypro.esmo.org/Meeting-Resourc...ciated-antiemetic-prophylaxis-Santarem-Study

AimNausea and vomiting are some of chemotherapy's most disabling side effects. Our main objective was to compare the impact in quality of life (QoL) of different antiemetics for chemotherapy-induced...

Date: 27 Sep 2014
Presenter: Bárbara Parente
Resources: Abstract
Topics: Anti-Cancer Agents & Biologic Therapy, Supportive Care, Non-Small-Cell Lung Cancer, Locally Advanced

http://oncologypro.esmo.org/Meeting-Resourc...ed-with-neoadjuvant-CCRT-followed-by-surgery

AimThe aim of this study was to evaluate the clinical implications of DNA methylation of tumor suppressor gene in pathologic complete responders in stage IIIA(N2) NSCLC patients treated with neoadjuvant CCRT followed by surgery.

Date: 27 Sep 2014
Presenter: Jae Hyun Kim
Resources: Abstract
Topics: Anti-Cancer Agents & Biologic Therapy, Non-Small-Cell Lung Cancer, Locally Advanced, Translational Research, Surgery and/or Radiotherapy of Cancer

http://oncologypro.esmo.org/Meeting-Resourc...-III-non-squamous-non-small-cell-lung-cancer

AimKRAS, a member of the RAS oncogene family, is known to be mutated at exon2 or exon3 in approximately 15%–30% of patients with advanced non-small cell lung cancer (NSCLC).

Date: 27 Sep 2014
Presenter: Shigehiro Yagishita
Resources: Abstract
Topics: Anti-Cancer Agents & Biologic Therapy, Non-Small-Cell Lung Cancer, Locally Advanced, Pathology/Molecular Biology, Translational Research

http://oncologypro.esmo.org/Meeting-Resourc...resected-non-small-cell-lung-cancer-patients

AimWe tested the hypothesis that the circulating tumor cells (CTCs) in preoperative peripheral blood (PPB) and intraoperative pulmonary venous blood (IPVB) could predict poor long-term survival in surgically resected NSCLC patients.

Date: 27 Sep 2014
Presenter: ZhiDong Liu
Resources: Abstract
Topics: Non-Small-Cell Lung Cancer, Locally Advanced, Translational Research

http://oncologypro.esmo.org/Meeting-Resourc...bjects-with-non-small-cell-lung-cancer-NSCLC

AimVeliparib (V; ABT-888) is a potent, orally bio-available PARP inhibitor that delays the repair of DNA damage induced by chemotherapeutic agents, triggering cell death and enhancing efficacy.

Date: 27 Sep 2014
Presenter: Hidenori Mizugaki
Resources: Abstract
Topics: Anti-Cancer Agents & Biologic Therapy, Non-Small-Cell Lung Cancer, Locally Advanced, Non-Small-Cell Lung Cancer, Metastatic

http://oncologypro.esmo.org/Meeting-Resourc...nced-lung-cancer-by-emphysema-quantification

AimRadiation pneumonitis (RP) is one of the most crucial adverse events of definitive chemoradiotherapy for the treatment of locally advanced lung cancer. Although chronic obstructive pulmonary disease ...

Date: 27 Sep 2014
Presenter: Shuntaro Tokunaga
Resources: Abstract
Topics: Anti-Cancer Agents & Biologic Therapy, Complications of Treatment, Non-Small-Cell Lung Cancer, Locally Advanced, Surgery and/or Radiotherapy of Cancer